| abstract |
There is a demand for an anti-human VEGF receptor Flt-1 antibody composition that is useful as a pharmaceutical having its effector function enhanced. Thus, there is provided a composition of antibody molecules capable of specifically binding human VEGF receptor Flt-1, the antibody molecules having in the Fc region thereof a conjugated sugar chain with an N-glycoside linked therewith, wherein the conjugated sugar chain with an N-glycoside linked therewith is a sugar chain having fucose not linked with the N-acetylglucosamine being a reduced terminal of the conjugated sugar chain. There are further provided a transformant capable of producing the antibody composition, a process for producing the antibody composition and a medical drug containing the antibody composition. |